Investing $1,000 a month with an average total return of 12% per annum would grow into $2.15 million after 27 years. That ...

Up 25% in 12 months, a leading fundie sees strong ongoing growth potential for this S&P/ASX 300 Index (ASX: XKO) stock.

Last week, the broker reaffirmed its buy rating and $40.20 price target on the ASX 200 share. This implies potential upside ...

Let's run the numbers and see how much an Australian investor would need in their superannuation fund to live off $65,000 a ...

The S&P/ASX 200 Index (ASX: XJO) is up 3% in 2025, with these three ASX 200 stocks doing a lot of the heavy lifting.

This S&P/ASX 300 Index (ASX: XKO) tech stock has delivered by strong returns in the last few years. Here’s why there could be ...

Goldman has a buy rating and $40.20 price target on its shares. Another ASX 200 share that is being described as a fallen ...

We reveal the forecast dividend amounts and dividend yields that analysts expect the largest ASX 200 financial shares to pay ...

Kogan.com Ltd (ASX: KGN) and Regis Resources Ltd (ASX: RRL) are two of four ASX shares falling on Friday. Here's ...

Apple may not be the exciting growth stock it was years ago, but could the key to its long-term success depend on its services business?

It's been a big week in finance, but little of what’s happening now will be consequential for our long-term investing returns.

In early trade, the ASX 200 biotech stock was up as much as 15% to $4.69. Its shares have since pulled back but remain up 3% ...